Trial Profile
An open label, multi-centre study of pasireotide LAR in addition to chemotherapy in patients with non-functioning, endocrine pancreatic tumors.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Jun 2012
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary) ; Antineoplastics
- Indications Endocrine gland neoplasms; Pancreatic cancer
- Focus Biomarker; Therapeutic Use
- 29 Jul 2011 New trial record